IL6 and metabolic dysfunction-associated steatotic liver disease: The overall findings clearly indicate that GDC-0449 and LED225 effectively reduce macrophage activation and proinflammatory cytokine expression (TNF-α, IL-1β, MCP1, and IL-6) as well as further NAFLD progression through direct binding to SMO and blocking of the Hh signaling pathway, supporting their potential utility as effective therapy for NAFLD-induced liver cancer [159].